Free Trial
→ Your trading day could end at 11 AM (From ProsperityPub) (Ad)

89bio Q2 2023 Earnings Report

89bio logo
$11.08 +0.12 (+1.05%)
As of 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Earnings HistoryForecast

89bio EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.44
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

89bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

89bio Announcement Details

Quarter
Q2 2023
Date
8/9/2023
Time
Q2 2023 Earnings Release

Conference Call Resources

Powered by Quartr

89bio Earnings Headlines

89bio's (ETNB) Sell (D-) Rating Reaffirmed at Weiss Ratings
February 20 at 3:11 AM | americanbankingnews.com
Insider Buying Surges in February, Especially in These 6 Stocks
February 9, 2025 | 247wallst.com
Market down? Do this now.
During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now, history is repeating itself. Here's the truth: Tariffs create uncertainty. Uncertainty drives investors to gold. And gold prices rise as a result. It's a cycle that's already beginning again—and it's your chance to profit. Why wait? Greed isn't always a bad thing—especially when it comes to protecting and growing your wealth. The smartest investors are already moving their money into gold, and you should too.
February 21, 2025 | Colonial Metals (Ad)
Institutional investors have a lot riding on 89bio, Inc. (NASDAQ:ETNB) with 58% ownership
February 6, 2025 | uk.finance.yahoo.com
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 6, 2025 | globenewswire.com
Wolfe Research Initiates Coverage of 89bio (ETNB) with Outperform Recommendation
February 5, 2025 | msn.com
See More 89bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 89bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 89bio and other key companies, straight to your email.

About 89bio

89bio (NASDAQ:ETNB), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

View 89bio Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles